

- **Name:** Vivek Subbiah
 - **Current Position & Affiliation:** Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
 - **Country:** USA
-

• Educational Background:**Degree-Granting Education**

- Sri Ramachandra Medical College & Research Institute, Chennai, India, MBBS, 2002, Bachelor of Medicine and Bachelor of Surgery

Postgraduate Training

- Clinical Internship, Medicine and Surgery, Sri Ramachandra Medical College & Research Institute, Chennai, India, Dr. K.V. Somasundaram, 2001-2002
- Visiting Scholar, Emergency Medicine, Stanford University Medical Center, Division of Emergency Medicine, Palo Alto, CA, Dr. Swaminatha Mahadevan, 2003-2003
- Clinical Internship, Internal Medicine and Pediatrics Combined Internship, Case Western Reserve University School of Medicine (Metrohealth Medical Center), Cleveland, OH, Dr. David Mansour, 7/2004-6/2005
- Clinical Residency, Internal Medicine and Pediatrics Combined Residency, Case Western Reserve University School of Medicine, Cleveland, OH, Dr. David Mansour, 7/2005-6/2008
- Clinical Fellowship, Pediatric Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Susan S. Kelly, 7/2008-6/2011
- Research Fellowship, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Razelle Kurzrock, 10/2009-6/2011
- Clinical Fellowship, Adult Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Robert Wolff, 7/2011-6/2012
- Heart of Leadership Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013-2014
- Heart of Leadership Program 2, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017-2018
- LEAD Program, Leadership Developmental Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019-2020

• Professional Experience:**Academic Appointments**

- Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-2018
- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The

University of Texas MD Anderson Cancer Center, Houston, TX, 2014-2018

- Assistant Professor, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014-2018
- Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018-present
- Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018-present
- Associate Professor, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018-present

• Professional Organizations:

Board Certification

- Education Commission for Foreign Medical Graduates (ECFMG), 2004
- Diplomate of American Board of Internal Medicine (ABIM)., 2008-2018
- Diplomate of American Board of Pediatrics (ABP), 2011-2021
- American Board of Medical Oncology, 2014-2024

• Main Scientific Publications:

1. Ganeshan D, Kambadakone A, Nikolaidis P, Subbiah V, Subbiah IM, Devine C. Current update on gallbladder carcinoma. *Abdom Radiol (NY)*. e-Pub 1/2021. PMID: 33386907.
2. Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. *Oncologist*. e-Pub 1/2021. PMID: 33491277.
3. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. *Invest New Drugs*. e-Pub 1/2021. PMID: 33415580
4. Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. *J Immunother Cancer* 9(2), 2/2021. PMID: PMC7898862.
5. Hegde A, Jayaprakash P, Couillaud CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Ileana Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. *Clin Cancer Res*. e-Pub 3/2021. PMID: 33771853.
6. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol*.

- e-Pub 3/2021. PMCID: PMC7985918
7. Groisberg R, Subbiah V. Combination therapies for Precision Oncology: The Ultimate Whack-A-Mole Game. *Clin Cancer Res.* e-Pub 3/2021. PMID: 33707180
 8. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol.* e-Pub 3/2021. PMCID: PMC7957448.
 9. Addeo A, Passaro A, Malapelle U, Luigi Banna G, Subbiah V, Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. *Cancer Treat Rev* 96:102179. e-Pub 3/2021. PMID: 33798954
 10. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlina AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. *Mol Cancer Res* 19(3):395-402, 3/2021. e-Pub 12/2020. PMID: 33323389.
 11. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Overview of Ocular Side Effect of Selinexor. *Oncologist.* e-Pub 3/2021. PMID: 33728727.
 12. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. *Oncologist.* e-Pub 3/2021. PMID: 33783054.
 13. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. *Br J Cancer.* e-Pub 3/2021. PMID: 33674736.
 14. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. *NPJ Precis Oncol* 5(1):21, 3/2021. e-Pub 3/2021. PMCID: PMC7979841.
 15. Demetri GD, Luke JJ, Hollebecque A, Powderly J, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, Yue H, Polepally AR, Purcell JW, Robinson R, Sharma P, Allison JP, Tolcher AW, Villalobos VM. First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. *Clin Cancer Res.* e-Pub 4/2021. PMID: 33820780.
 16. Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. *J Immunother Cancer* 9(4), 4/2021. PMCID: PMC8051405.
 17. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. *Invest New Drugs.* e-Pub 4/2021. PMID: 33909232
 18. Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HHF, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY,

- Kherani JF, Huang X, Kang S, Drilon A. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. *Clin Cancer Res. e-Pub* 6/2021. PMID: 34088726.
19. Shen T, Hu X, Liu X, Subbiah V, Mooers BHM, Wu J. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. *NPJ Precis Oncol* 5(1):48, 6/2021. e-Pub 6/2021. PMCID: PMC8184971.
 20. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. *Onco Targets Ther* 14:3037-3049, 2021. e-Pub 5/2021. PMCID: PMC8114359.
 21. Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. *Ann Oncol* 32(6):817-819, 6/2021. e-Pub 2/2021. PMCID: PMC8119360.
 22. Desai A, Subbiah IM, Subbiah V. Advances in cancer research dissemination through the pandemic and beyond. *Ann Oncol* 32(6):689-693, 6/2021. e-Pub 2/2021. PMID: 33636283.
 23. Reddy NK, Subbiah V. Right to Try, expanded access use, Project Facilitate, and clinical trial reform. *Ann Oncol. e-Pub* 6/2021. PMID: 34166758.
 24. Abi Jaoude J, Kouzy R, Ghabach M, Patel R, Pasalic D, Ghossain E, Miller AB, Lin TA, Verma V, Fuller CD, Subbiah V, Minsky BD, Ludmir EB, Taniguchi CM. Food and Drug Administration approvals in phase 3 Cancer clinical trials. *BMC Cancer* 21(1):695, 6/2021. e-Pub 6/2021. PMCID: PMC8196526
 25. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol* 22(7):959-969, 7/2021. e-Pub 6/2021. PMID: 34118197.